Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Balchem Earnings Call: Key Takeaways

Balchem delivered record Q3 results with 8.6% revenue growth and 29 consecutive quarters of adjusted EBITDA growth, driven by specialty nutrients and favorable product mix despite inflationary raw material pressures.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthH&H $188M (+8.1%), ANH $63M (+11.7%), Specialty $37M (+4.5%).
Mgmt ConfidenceHigh; cited 29 consecutive quarters of year-over-year adjusted EBITDA growth.
Demand VisibilityHealthy demand across majority of businesses; positive long-term outlook for nutrients.
Margin TrendsGross margin expanded 70 bps to 36.4% via favorable product mix.
Op. LeverageOperating expenses rose to $43M from $41M due to higher compensation.
Pricing PowerSuccessfully passed through raw material inflation dollar-for-dollar to customers.
Vol vs PriceGrowth driven by higher sales volumes and favorable product mix.
Segment GrowthANH outperformed with 11.7% growth; H&H record sales of $188M.
New ClientsExploring beauty industry partnerships; upcoming international sports team partnership announcement.
Capex & DebtReduced net borrowings by $28M; net leverage ratio at 0.2x.
RegulatoryEU anti-dumping duties helping; filed for anti-dumping duties in US.
CommentaryStrategic focus on science-backed branded ingredients like VitaCholine and K2VITAL.
New LaunchesNext-generation encapsulated methionine launched October 1st; new encapsulated lysine driving growth.

Growth

Consolidated revenue grew 8.6% to $291M; H&H up 8.1%, ANH up 11.7%, Specialty up 4.5%.

Outlook

Management expects Q4 to be sequentially lower due to seasonality but deliver healthy year-over-year growth.

Risks

Management pivoted on specific inventory reduction timelines, citing geopolitical risks and upcoming product launch safety stocks.

Source

The company's earnings call, NASDAQ: BCPC, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Balchem Corp: key numbers

Share price
$171.48Close, Nov 16
Market cap
$5.45B
Shares outstanding
31.78MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Chemicals & Allied ProductsSIC 2800

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Balchem Corp

All →
4:19 PM ET 10-Q
Financial Results ▶ Call

Balchem Q3 2026 Results: Net Income $46.7M, Up 16.0% YoY

Balchem Corp reported net sales of $290.7 million for the third quarter of 2026, a 8.6% increase compared to the prior year, with net earnings rising to $46.7 million. For the nine months ended September 30, 2026, the company generated $156.5 million in cash from operations while significantly increasing inventory levels and continuing its common stock repurchase program.

Key figure
Net income $46.7M · +16.0% YoY
7:21 AM ET 8-K
Financial Results

Balchem Financial Results

Balchem Corporation reported record third quarter 2026 financial results, with net sales increasing 8.6% year-over-year to $290.7 million. The company achieved growth across all three reporting segments and repurchased approximately $28 million of common stock during the quarter.

Term
Q3 2026

“Balchem delivered another excellent quarter, with healthy growth across all three of our reporting segments and record consolidated quarterly net sales, net earnings, and adjusted EBITDA.”

Ted Harris, Chairman, President and CEO

“With strong results through the first nine months of the year and a healthy balance sheet, Balchem is well positioned to continue executing our strategic growth initiatives, and we remain excited about the future of our company.”

Ted Harris, Chairman, President and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.